Absci (ABSI)
Market Price (8/24/2026): $9.56 | Market Cap: $1.5 BilSector: Health Care | Industry: Biotechnology
Absci (ABSI)
Market Price (8/24/2026): $9.56Market Cap: $1.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.65 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -131 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8411% Expensive valuation multiplesP/SPrice/Sales ratio is 963x Stock price has recently run up significantly6M Rtn6 month market price return is 260%, 12M Rtn12 month market price return is 263% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -62%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -32%, Rev Chg QQuarterly Revenue Change % is -46% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1171% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6924%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6988% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 285% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% High stock price volatilityVol 12M is 105% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% Key risksABSI key risks include [1] significant financial losses and high cash burn as a pre-revenue company, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.65 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -131 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -8411% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 963x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 260%, 12M Rtn12 month market price return is 263% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -62%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -32%, Rev Chg QQuarterly Revenue Change % is -46% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 1171% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6924%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -6988% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 285% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% |
| High stock price volatilityVol 12M is 105% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 24% |
| Key risksABSI key risks include [1] significant financial losses and high cash burn as a pre-revenue company, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Absci (ABSI) stock has gained about 90% since 4/30/2026 because of the following key factors:
1. Positive Interim Phase 1 Data for ABS-201.
Absci reported positive interim Phase 1 data from its HEADLINE trial for ABS-201 in June 2026, indicating the study medication was well-tolerated with favorable safety data. Preliminary pharmacokinetic (PK) modeling supported a targeted dosing interval of two or three injections over a six-month period, which is a key factor for patient convenience and potential market differentiation.
2. Strategic Equity Investment from Eli Lilly & Company and Successful Financing.
In June 2026, Absci completed a $100 million underwritten offering, which notably included a $40 million strategic equity investment from Eli Lilly & Company. This significant capital infusion increased Absci's cash, cash equivalents, and marketable securities to $201.1 million as of June 30, 2026, extending the company's cash runway into the second half of 2028 and providing strong financial backing for its clinical programs.
Show more
Absci (ABSI) stock has gained about 90% since 4/30/2026 because of the following key factors:
1. Positive Interim Phase 1 Data for ABS-201.
Absci reported positive interim Phase 1 data from its HEADLINE trial for ABS-201 in June 2026, indicating the study medication was well-tolerated with favorable safety data. Preliminary pharmacokinetic (PK) modeling supported a targeted dosing interval of two or three injections over a six-month period, which is a key factor for patient convenience and potential market differentiation.
2. Strategic Equity Investment from Eli Lilly & Company and Successful Financing.
In June 2026, Absci completed a $100 million underwritten offering, which notably included a $40 million strategic equity investment from Eli Lilly & Company. This significant capital infusion increased Absci's cash, cash equivalents, and marketable securities to $201.1 million as of June 30, 2026, extending the company's cash runway into the second half of 2028 and providing strong financial backing for its clinical programs.
3. Pipeline Expansion and Advancement of ABS-201 into Endometriosis.
Absci expanded its pipeline by announcing ABS-202 for an undisclosed inflammation and immunology (I&I) indication on May 7, 2026. Additionally, ABS-201, initially for pattern hair loss, is also being developed for endometriosis, with the initiation of a Phase 2 clinical trial anticipated in fiscal Q4 2026, broadening its potential market opportunities.
Show less
Stock Movement Drivers
Fundamental Drivers
The 92.0% change in ABSI stock from 4/30/2026 to 8/23/2026 was primarily driven by a 259.6% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.97 | 9.55 | 92.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 2 | -44.2% |
| P/S Multiple | 267.9 | 963.4 | 259.6% |
| Shares Outstanding (Mil) | 151 | 157 | -4.3% |
| Cumulative Contribution | 92.0% |
Market Drivers
4/30/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| ABSI | 92.0% | |
| Market (SPY) | 6.5% | 40.1% |
| Sector (XLV) | 19.6% | 12.3% |
Fundamental Drivers
The 219.4% change in ABSI stock from 1/31/2026 to 8/23/2026 was primarily driven by a 530.9% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.99 | 9.55 | 219.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 2 | -44.5% |
| P/S Multiple | 152.7 | 963.4 | 530.9% |
| Shares Outstanding (Mil) | 144 | 157 | -8.7% |
| Cumulative Contribution | 219.4% |
Market Drivers
1/31/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| ABSI | 219.4% | |
| Market (SPY) | 11.0% | 40.4% |
| Sector (XLV) | 13.3% | 16.4% |
Fundamental Drivers
The 237.5% change in ABSI stock from 7/31/2025 to 8/23/2026 was primarily driven by a 1217.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.83 | 9.55 | 237.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 5 | 2 | -67.6% |
| P/S Multiple | 73.2 | 963.4 | 1217.0% |
| Shares Outstanding (Mil) | 124 | 157 | -21.0% |
| Cumulative Contribution | 237.5% |
Market Drivers
7/31/2025 to 8/23/2026| Return | Correlation | |
|---|---|---|
| ABSI | 237.5% | |
| Market (SPY) | 22.2% | 40.4% |
| Sector (XLV) | 35.6% | 17.8% |
Fundamental Drivers
The 334.1% change in ABSI stock from 7/31/2023 to 8/23/2026 was primarily driven by a 2866.5% change in the company's P/S Multiple.| (LTM values as of) | 7312023 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.20 | 9.55 | 334.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 2 | -74.8% |
| P/S Multiple | 32.5 | 963.4 | 2866.5% |
| Shares Outstanding (Mil) | 91 | 157 | -41.9% |
| Cumulative Contribution | 334.1% |
Market Drivers
7/31/2023 to 8/23/2026| Return | Correlation | |
|---|---|---|
| ABSI | 334.1% | |
| Market (SPY) | 73.2% | 38.0% |
| Sector (XLV) | 36.3% | 21.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ABSI Return | -62% | -74% | 100% | -38% | 33% | 166% | -57% |
| Peers Return | -42% | -52% | 10% | -55% | 12% | 69% | -74% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| ABSI Win Rate | 33% | 25% | 42% | 33% | 58% | 62% | |
| Peers Win Rate | 36% | 37% | 48% | 35% | 55% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ABSI Max Drawdown | - | -79% | -66% | -61% | -62% | -43% | |
| Peers Max Drawdown | -68% | -66% | -64% | -67% | -55% | -40% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SDGR, RXRX, RLAY, ABCL, DNA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | ABSI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -59.9% | -18.8% |
| % Gain to Breakeven | 149.2% | 23.1% |
| Time to Breakeven | 396 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -46.3% | -9.5% |
| % Gain to Breakeven | 86.1% | 10.5% |
| Time to Breakeven | 41 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -55.3% | -6.7% |
| % Gain to Breakeven | 123.9% | 7.1% |
| Time to Breakeven | 212 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -68.4% | -24.5% |
| % Gain to Breakeven | 216.7% | 32.4% |
| Time to Breakeven | 1337 days | 427 days |
In The Past
Absci's stock fell -59.9% during the 2025 US Tariff Shock. Such a loss loss requires a 149.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ABSI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -59.9% | -18.8% |
| % Gain to Breakeven | 149.2% | 23.1% |
| Time to Breakeven | 396 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -46.3% | -9.5% |
| % Gain to Breakeven | 86.1% | 10.5% |
| Time to Breakeven | 41 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -55.3% | -6.7% |
| % Gain to Breakeven | 123.9% | 7.1% |
| Time to Breakeven | 212 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -68.4% | -24.5% |
| % Gain to Breakeven | 216.7% | 32.4% |
| Time to Breakeven | 1337 days | 427 days |
In The Past
Absci's stock fell -59.9% during the 2025 US Tariff Shock. Such a loss loss requires a 149.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Absci (ABSI)
Absci Corporation (ABSI) is a drug and target discovery company that provides biologic drug candidates and production cell lines. The company's unique value proposition lies in its integrated drug creation platform, which unifies the typically separate processes of drug discovery and cell line development into a single, streamlined process.
Through this innovative platform, Absci delivers its main products: novel biologic drug candidates and optimized production cell lines. By merging these critical stages, Absci aims to accelerate the development timeline, improve the efficiency, and enhance the success rate of bringing new biologic therapies to market.
Absci primarily serves partners, which are typically pharmaceutical and biotechnology companies seeking advanced solutions for drug development. The company currently focuses on serving these partners within the United States, utilizing its platform to help bring promising biologic therapeutics closer to patients.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Absci:
- Shopify for biologic drug creation: Absci provides an integrated platform that enables other companies to discover and develop biologic drug candidates and their production methods, much like Shopify provides a platform for businesses to build and operate online stores.
- A 'design-build' firm for new biologic drugs: Similar to how a design-build firm integrates architectural design and construction into a single, streamlined process, Absci unifies the discovery of biologic drugs with the development of their production cell lines.
AI Analysis | Feedback
- Biologic Drug Candidates: Absci develops potential therapeutic drug compounds for its partners.
- Production Cell Lines: Absci creates specialized cell lines designed for the efficient manufacturing of biologic drugs.
- Integrated Drug Creation Platform: This proprietary platform unifies the drug discovery and cell line development processes to accelerate the creation of biologics.
AI Analysis | Feedback
Major Customers of Absci Corporation (ABSI)
Absci Corporation, a drug and target discovery company, primarily sells its integrated drug creation platform and services to other companies in the pharmaceutical and biotechnology industries. Its major customers, also referred to as partners in its collaboration agreements, include:
- Astellas Pharma Inc. (TYO: 4503)
- Merck KGaA, Darmstadt, Germany (FWB: MRK)
AI Analysis | Feedback
AI Analysis | Feedback
Sean McClain, Founder, CEO & Director
Sean McClain founded Absci in 2011, starting the company from a basement lab at the age of 22. He has since led Absci to become a publicly listed company with a valuation nearing $2 billion. Under his leadership, Absci has established key partnerships with companies such as Merck, AstraZeneca, and NVIDIA. He holds a Bachelor of Science degree in Molecular and Cellular Biology from the University of Arizona. McClain skipped the traditional academic route after college to co-found Absci.
Zach Jonasson, PhD, Chief Financial Officer & Chief Business Officer
Zach Jonasson was appointed Chief Financial Officer and Chief Business Officer in August 2023. He is a co-founder and Managing General Partner of Phoenix Venture Partners (PVP) and Convergent Ventures, both venture capital firms. Dr. Jonasson previously served on Absci's Board of Directors from 2016, including as chairman from April 2016 to January 2021. Prior to his roles at PVP, he was the CEO and co-founder of Comera Life Sciences, where he built the company from the concept stage and secured multiple collaborations. He also co-founded and served as Head of Business Development at Crop Enhancement. Phoenix Venture Partners (PVP) was Absci's largest shareholder before its IPO and led the company's Series A funding round in 2016, indicating his involvement with companies backed by private equity.
Ransi Somaratne, M.D., FACC, MBA, Chief Medical Officer
Dr. Ransi Somaratne was appointed Chief Medical Officer in March 2026, leading the clinical development strategy for Absci's AI-designed therapeutics pipeline. He joined Absci from Vertex Pharmaceuticals, where he was the Senior Vice President of Clinical Development. His career includes previous scientific leadership roles at BioMarin Pharmaceutical and Amgen. A cardiologist and internist by training, Dr. Somaratne earned his Doctor of Medicine (MD) degree from Albany Medical College and an MBA from the University of North Carolina at Chapel Hill. He has contributed to multiple pioneering clinical development programs.
Shelby Walker, JD, Chief Legal Officer
Shelby Walker serves as the Chief Legal Officer of Absci.
Amir Shanehsazzadeh, Chief AI Officer
Amir Shanehsazzadeh is the Chief AI Officer at Absci. He leads Absci's AI Biologics Discovery and Engineering team, overseeing the development, experimental validation, and deployment of Absci's AI Platform for de novo antibody design and optimization.
AI Analysis | Feedback
Key Risks to Absci (ABSI)
- Clinical Trial Execution and Product Commercialization: Absci, as an AI-driven drug discovery company, currently has no commercialized therapies, and its future success is highly dependent on its ability to successfully advance its pipeline candidates through clinical trials and ultimately achieve regulatory approval and commercialization. The value of the company is heavily concentrated in the success of its pipeline, such as ABS-201, with no guarantee that any of these assets will reach the market. The transition from laboratory success to clinical success and commercialization represents a significant hurdle for Absci.
- Financial Condition and Need for Additional Capital: Absci is deeply unprofitable and operates with a substantial cash burn rate, primarily due to significant research and development expenses as it transitions from a service-based platform to a clinical-stage biopharmaceutical company. While the company projects a cash runway into the first half of 2028, ongoing widening losses and the capital-intensive nature of drug development indicate a continued need to raise additional capital through equity issuances, convertible debt, or partnerships to fund operations and advance its programs. A failure to secure necessary funding could jeopardize its long-term survival.
- Intense Competition: Absci operates in a highly competitive and rapidly evolving biotechnology landscape, specifically in the AI-driven drug discovery sector. It faces competition from both other emerging AI biotech companies and established pharmaceutical companies expanding their internal AI capabilities. This increasing competition could make Absci's growth less certain and impact its ability to secure partnerships or differentiate its platform and drug candidates.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable market for Absci's main products and services, which involve an integrated drug creation platform that leverages generative artificial intelligence (AI) and synthetic biology for drug and target discovery, can be primarily characterized by the "AI in Drug Discovery" market.
Globally, the artificial intelligence in drug discovery market was valued at approximately USD 2.4 billion in 2024. This market is projected to experience substantial growth, with estimates placing its value at USD 5.1 billion in 2026 and reaching USD 13.4 billion by 2035. Another projection indicates the global AI in drug discovery market is expected to grow from USD 1.86 billion in 2024 to USD 6.89 billion by 2029, at a compound annual growth rate (CAGR) of 29.9%. Furthermore, the AI-enabled drug discovery market is estimated to be valued at USD 8.1765 billion in 2026 and is projected to reach USD 33.9516 billion by 2036, with a CAGR of 15.3%. One source also estimates the global AI in drug discovery market to grow from USD 19.89 billion in 2025 to approximately USD 133.92 billion by 2034.
In the United States, a significant region for Absci's operations, the artificial intelligence in drug discovery market was valued at USD 1.4 billion in 2025, growing from USD 1.1 billion in 2024. North America held a substantial share of the global artificial intelligence in drug discovery industry, accounting for 47.7% in 2025. Projections also suggest that North America is poised to capture 67% of the overall AI in drug discovery market share by 2035.
The broader "AI in Pharma and Biotech" market, which encompasses Absci's activities, was valued at USD 6.63 billion globally in 2025. This market is projected to grow from USD 8.54 billion in 2026 to an estimated USD 154.10 billion by 2034, exhibiting a CAGR of 43.55% during that forecast period. North America dominated this global market with a 51.73% market share in 2025.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Absci (ABSI)
Absci Corporation (ABSI) is poised for future revenue growth over the next 2-3 years, driven primarily by the advancement of its proprietary drug pipeline, the expansion of its drug creation partnerships, and the continued leverage of its artificial intelligence (AI)-driven integrated drug creation platform.
- Advancement of Proprietary Clinical Pipeline: A key driver of future revenue for Absci is the successful progression of its internal therapeutic candidates through clinical trials. A primary focus is ABS-201, an AI-designed antibody for androgenetic alopecia (AGA) and endometriosis. The company initiated Phase 1/2a trials for AGA in December 2025, with interim efficacy data anticipated in the second half of 2026. A Phase 2 trial for ABS-201 in endometriosis is expected to commence in Q4 2026, with potential proof-of-concept data in the second half of 2027. Additionally, Absci plans to initiate Phase 1 clinical studies for ABS-101 (an anti-TL1A antibody) in the first half of 2025 (or "in the coming months" as of March 2025) and is exploring partnership opportunities for this asset post-Phase I. Successful clinical milestones from these and other preclinical programs like ABS-301 and ABS-501 are expected to unlock substantial milestone payments or royalties.
- Expansion of Drug Creation Partnerships: Absci aims to secure new drug creation partnerships, including with large pharmaceutical companies, in 2025. The company has already established collaborations with entities such as Owkin, Twist Bioscience, Invetx, Memorial Sloan Kettering Cancer Center, and previously with major pharma companies like Merck and Sanofi. These partnerships validate Absci's technology, provide an ongoing revenue stream through research fees and upfront payments, and offer the potential for significant milestone and royalty payments upon successful drug development and commercialization.
- Leveraging the AI-Driven Integrated Drug Creation Platform: Absci's core competitive advantage lies in its Integrated Drug Creation™ Platform, which unifies drug discovery and cell line development using generative AI and high-throughput wet lab technologies. This platform is designed to significantly reduce the time and cost associated with developing new biologic drugs. Its scalability and increasing efficiency with each new project are critical for Absci's competitiveness. Strategic collaborations, such as the January 2025 partnership with AMD to deploy high-performance computing for AI drug discovery workloads, underscore the company's commitment to advancing this foundational technology. The platform's success is seen as the primary driver enabling both internal pipeline advancements and attractive partnership opportunities.
AI Analysis | Feedback
Share Issuance
- In July 2025, Absci completed an underwritten public offering of common stock, raising approximately $50 million in gross proceeds.
- Concurrently in July 2025, the company raised an additional approximately $14 million through its at-the-market (ATM) facility, bringing the total gross proceeds from these capital raises to approximately $64 million.
Inbound Investments
- In January 2025, AMD made a $20 million strategic equity investment in Absci, structured as a private investment in public equity (PIPE), as part of a strategic collaboration.
Capital Expenditures
- A primary focus of capital allocation is for the advancement of Absci's internally developed programs, such as ABS-101 and ABS-201, through preclinical and clinical development.
- Proceeds from stock offerings are also designated for continued investment in the company's Integrated Drug Creation™ platform.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 82.4% | 124.2% | CAH 394% · MCK 340% · COR 184% |
| Health Care Services | 20 | 20.6% | 46.6% | 7.5% | HIMS 337% · RDNT 157% · DGX 80% |
| Managed Health Care | 8 | 29.7% | -3.0% | 0.6% | OSCR 158% · HQY 63% · ELV 14% |
| Health Care Facilities | 24 | 7.9% | -0.8% | -16.4% | THC 286% · NHC 265% · ENSG 123% |
| Health Care Equipment | 51 | -4.5% | -4.5% | -17.6% | POCI 11300% · UFPT 373% · GKOS 260% |
| Health Care Supplies | 12 | 33.9% | -12.1% | -26.0% | LNTH 297% · HAE 78% · MMSI 29% |
| Pharmaceuticals | 63 | 4.5% | 4.1% | -38.2% | LQDA 2499% · INDV 1253% · ETON 1190% |
| Health Care Technology | 21 | -19.9% | -53.0% | -72.5% | SPOK 115% · HSTM -1% · VEEV -23% |
| Life Sciences Tools & Services | 108 | -2.5% | -28.0% | -72.6% | SNWV 1782% · MEDP 245% · ELMD 225% |
| Biotechnology ← | 365 | 7.8% | -24.2% | -78.3% | BRTX 107550% · CELZ 1771% · DNTH 1543% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Absci Earnings Notes | 12/16/2025 | |
| With Absci Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.44 |
| Mkt Cap | 1.7 |
| Rev LTM | 60 |
| Op Inc LTM | -250 |
| FCF LTM | -153 |
| FCF 3Y Avg | -198 |
| CFO LTM | -149 |
| CFO 3Y Avg | -165 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -3.8% |
| Rev Chg 3Y Avg | 6.2% |
| Rev Chg Q | -48.4% |
| QoQ Delta Rev Chg LTM | -14.7% |
| Op Inc Chg LTM | 12.9% |
| Op Inc Chg 3Y Avg | -5.3% |
| Op Mgn LTM | -663.7% |
| Op Mgn 3Y Avg | -787.7% |
| QoQ Delta Op Mgn LTM | -93.6% |
| CFO/Rev LTM | -401.0% |
| CFO/Rev 3Y Avg | -431.9% |
| FCF/Rev LTM | -418.8% |
| FCF/Rev 3Y Avg | -516.9% |
Price Behavior
| Market Price | $9.55 | |
| Market Cap ($ Bil) | 1.5 | |
| First Trading Date | 07/22/2021 | |
| Distance from 52W High | -17.8% | |
| 50 Days | 200 Days | |
| DMA Price | $8.88 | $4.96 |
| DMA Trend | up | up |
| Distance from DMA | 7.6% | 92.6% |
| 3M | 1YR | |
| Volatility | 129.1% | 105.8% |
| Downside Capture | 168.13 | 310.12 |
| Upside Capture | 443.04 | 400.73 |
| Correlation (SPY) | 39.4% | 41.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.97 | 3.41 | 3.69 | 3.14 | 3.24 | 2.39 |
| Up Beta | 9.14 | 4.35 | 3.87 | 1.79 | 1.82 | 1.58 |
| Down Beta | 1.03 | 7.79 | 6.50 | 5.66 | 4.13 | 2.21 |
| Up Capture | -119% | 245% | 493% | 785% | 1646% | 22085% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 7 | 21 | 31 | 65 | 125 | 366 |
| Down Capture | 435% | 115% | 179% | 169% | 177% | 112% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 14 | 21 | 31 | 59 | 123 | 372 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABSI | |
|---|---|---|---|---|
| ABSI | 273.5% | 105.3% | 1.71 | - |
| Sector ETF (XLV) | 28.8% | 16.0% | 1.39 | 18.1% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 41.0% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 18.3% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | -11.1% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 15.9% |
| Bitcoin (BTCUSD) | -31.6% | 44.1% | -0.73 | 23.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABSI | |
|---|---|---|---|---|
| ABSI | -16.8% | 97.9% | 0.25 | - |
| Sector ETF (XLV) | 7.1% | 15.1% | 0.28 | 22.7% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 38.7% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 11.5% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | 0.9% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 30.4% |
| Bitcoin (BTCUSD) | 10.4% | 52.8% | 0.38 | 21.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABSI | |
|---|---|---|---|---|
| ABSI | -7.5% | 98.1% | 0.29 | - |
| Sector ETF (XLV) | 10.7% | 16.7% | 0.52 | 22.9% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 38.6% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 11.3% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 1.3% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 30.3% |
| Bitcoin (BTCUSD) | 63.1% | 66.1% | 1.03 | 21.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/20/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 1.0% | -6.0% | |
| 5/7/2026 | 2.6% | -3.7% | 13.9% |
| 11/12/2025 | -22.4% | -15.9% | -0.3% |
| 5/13/2025 | -1.7% | -5.7% | -4.1% |
| 3/18/2025 | -3.2% | -0.3% | -1.0% |
| 11/12/2024 | -15.0% | -35.3% | 2.3% |
| 8/14/2024 | 11.0% | 16.6% | 4.6% |
| 5/14/2024 | -4.5% | -8.9% | -2.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 5 |
| # Negative | 9 | 11 | 13 |
| Median Positive | 3.5% | 6.0% | 13.9% |
| Median Negative | -12.7% | -6.0% | -4.2% |
| Max Positive | 14.0% | 41.4% | 97.1% |
| Max Negative | -22.4% | -37.2% | -45.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/11/2026 | 1.0% | -6.0% | |
| 5/7/2026 | 2.6% | -3.7% | 13.9% |
| 11/12/2025 | -22.4% | -15.9% | -0.3% |
| 5/13/2025 | -1.7% | -5.7% | -4.1% |
| 3/18/2025 | -3.2% | -0.3% | -1.0% |
| 11/12/2024 | -15.0% | -35.3% | 2.3% |
| 8/14/2024 | 11.0% | 16.6% | 4.6% |
| 5/14/2024 | -4.5% | -8.9% | -2.0% |
| 3/21/2024 | 3.7% | 8.8% | -6.3% |
| 11/14/2023 | 0.0% | -2.9% | 97.1% |
| 8/14/2023 | 5.4% | 0.0% | -4.2% |
| 5/15/2023 | -8.6% | 41.4% | 31.2% |
| 3/30/2023 | 4.2% | 3.0% | -25.6% |
| 11/9/2022 | 3.3% | 1.5% | -5.2% |
| 8/11/2022 | 14.0% | 3.1% | -1.4% |
| 5/11/2022 | -12.7% | -6.0% | -17.5% |
| 3/22/2022 | 0.7% | 12.4% | -2.5% |
| 11/9/2021 | -21.1% | -37.2% | -36.3% |
| 9/7/2021 | -14.1% | -29.2% | -45.1% |
| SUMMARY STATS | |||
| # Positive | 10 | 8 | 5 |
| # Negative | 9 | 11 | 13 |
| Median Positive | 3.5% | 6.0% | 13.9% |
| Median Negative | -12.7% | -6.0% | -4.2% |
| Max Positive | 14.0% | 41.4% | 97.1% |
| Max Negative | -22.4% | -37.2% | -45.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/24/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/24/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/22/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 09/07/2021 | 10-Q |
| 03/31/2021 | 07/15/2021 | S-1/A |
Insider Activity
Updated 8/7/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Szela, Mary T | Direct | Buy | 7062026 | 11.54 | 12,900 | 148,866 | 245,802 | Form | |
| 2 | Pangalos, Menelas N | Direct | Buy | 5132026 | 5.36 | 37,453 | 200,748 | 1,245,171 | Form | |
| 3 | Busch, Andreas | Chief Innovation Officer | Direct | Buy | 3162026 | 2.29 | 100,000 | 229,000 | 965,111 | Form |
| 4 | Pangalos, Menelas N | Direct | Buy | 3032026 | 2.74 | 75,095 | 205,760 | 518,011 | Form | |
| 5 | McClain, Sean | Chief Executive Officer | Direct | Sell | 2032026 | 2.99 | 26,761 | 80,015 | 24,920,355 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Szela, Mary T | Direct | Buy | 7062026 | 11.54 | 12,900 | 148,866 | 245,802 | Form | |
| 2 | Pangalos, Menelas N | Direct | Buy | 5132026 | 5.36 | 37,453 | 200,748 | 1,245,171 | Form | |
| 3 | Busch, Andreas | Chief Innovation Officer | Direct | Buy | 3162026 | 2.29 | 100,000 | 229,000 | 965,111 | Form |
| 4 | Pangalos, Menelas N | Direct | Buy | 3032026 | 2.74 | 75,095 | 205,760 | 518,011 | Form | |
| 5 | McClain, Sean | Chief Executive Officer | Direct | Sell | 2032026 | 2.99 | 26,761 | 80,015 | 24,920,355 | Form |
| 6 | Jonasson, Zachariah | CFO / CBO | Direct | Sell | 2032026 | 2.99 | 17,496 | 52,313 | 1,146,779 | Form |
| 7 | Van, Houten Frans | Direct | Buy | 12092025 | 3.72 | 40,000 | 148,800 | 235,550 | Form | |
| 8 | Pangalos, Menelas N | Direct | Buy | 9222025 | 2.66 | 95,785 | 254,788 | 303,134 | Form | |
| 9 | Bedrick, Todd | SVP, CAO | Direct | Buy | 9222025 | 2.70 | 10,000 | 27,000 | 487,156 | Form |
Investor Activity (13F)
Updated Aug 24, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.